FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276391444> ?p ?o ?g. }

• W2276391444 endingPage "1001" @default.
• W2276391444 startingPage "991" @default.
• W2276391444 abstract "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns. Bevacizumab has been linked with stroke, bleeding events, and wound-healing complications in other tumor types; these events are of particular concern for glioblastoma (highly vascular tumors that are usually resected). Published data on the interaction of bevacizumab with radiotherapy/temozolomide are also limited. We report safety data from a phase III randomized trial (Avastin in Glioblastoma), focusing on these considerations.Eligible patients received: radiotherapy and temozolomide plus bevacizumab/placebo, 6 cycles; a 4-week treatment break; temozolomide plus bevacizumab/placebo, 6 cycles; and bevacizumab/placebo until progression. Data on adverse events (AEs) were collected throughout.Bevacizumab-treated patients (n = 461) had a longer median safety follow-up time (12.3 vs 8.5 mo), and a higher proportion completed 6 cycles of maintenance temozolomide (64.6% vs 36.9%) versus placebo (n = 450). The incidences of relevant AEs (bevacizumab vs placebo, respectively) were: arterial thromboembolic events (5.9% vs 1.6%); cerebral hemorrhage (3.3% vs 2.0%); wound-healing complications (6.9% vs 4.7%); thrombocytopenia (34.1% vs 27.3%); radiotherapy-associated skin injury (8.2% vs 9.3%); alopecia (39.0% vs 36.0%); gastrointestinal perforation (including gastrointestinal abscesses and fistulae, 1.7% vs 0.4%); and radiotherapy-associated injury (0.4% vs 0.0%). Overall, 15.8% and 23.8% of bevacizumab- and placebo-treated patients had surgery (including biopsy) after progression. Within 30 days of postprogression surgery, AE incidence was 10.9% (bevacizumab) and 23.4% (placebo).The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery." @default.
• W2276391444 created "2016-06-24" @default.
• W2276391444 creator A5001810357 @default.
• W2276391444 creator A5006549117 @default.
• W2276391444 creator A5012219489 @default.
• W2276391444 creator A5042329751 @default.
• W2276391444 creator A5044767725 @default.
• W2276391444 creator A5060245733 @default.
• W2276391444 creator A5063511816 @default.
• W2276391444 creator A5075387803 @default.
• W2276391444 creator A5080482957 @default.
• W2276391444 creator A5088507451 @default.
• W2276391444 date "2016-01-24" @default.
• W2276391444 modified "2023-10-01" @default.
• W2276391444 title "Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy" @default.
• W2276391444 cites W1482109403 @default.
• W2276391444 cites W2004291012 @default.
• W2276391444 cites W2013692234 @default.
• W2276391444 cites W2049809527 @default.
• W2276391444 cites W2096287682 @default.
• W2276391444 cites W2108119601 @default.
• W2276391444 cites W2124736921 @default.
• W2276391444 cites W2127745545 @default.
• W2276391444 cites W2128369559 @default.
• W2276391444 cites W2132697290 @default.
• W2276391444 cites W2135257773 @default.
• W2276391444 cites W2156330848 @default.
• W2276391444 cites W2158681922 @default.
• W2276391444 cites W2165871546 @default.
• W2276391444 cites W2167923186 @default.
• W2276391444 cites W2325421340 @default.
• W2276391444 doi "https://doi.org/10.1093/neuonc/nov300" @default.
• W2276391444 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4896538" @default.
• W2276391444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26809751" @default.
• W2276391444 hasPublicationYear "2016" @default.
• W2276391444 type Work @default.
• W2276391444 sameAs 2276391444 @default.
• W2276391444 citedByCount "34" @default.
• W2276391444 countsByYear W22763914442016 @default.
• W2276391444 countsByYear W22763914442017 @default.
• W2276391444 countsByYear W22763914442018 @default.
• W2276391444 countsByYear W22763914442019 @default.
• W2276391444 countsByYear W22763914442020 @default.
• W2276391444 countsByYear W22763914442021 @default.
• W2276391444 countsByYear W22763914442022 @default.
• W2276391444 countsByYear W22763914442023 @default.
• W2276391444 crossrefType "journal-article" @default.
• W2276391444 hasAuthorship W2276391444A5001810357 @default.
• W2276391444 hasAuthorship W2276391444A5006549117 @default.
• W2276391444 hasAuthorship W2276391444A5012219489 @default.
• W2276391444 hasAuthorship W2276391444A5042329751 @default.
• W2276391444 hasAuthorship W2276391444A5044767725 @default.
• W2276391444 hasAuthorship W2276391444A5060245733 @default.
• W2276391444 hasAuthorship W2276391444A5063511816 @default.
• W2276391444 hasAuthorship W2276391444A5075387803 @default.
• W2276391444 hasAuthorship W2276391444A5080482957 @default.
• W2276391444 hasAuthorship W2276391444A5088507451 @default.
• W2276391444 hasBestOaLocation W22763914441 @default.
• W2276391444 hasConcept C126322002 @default.
• W2276391444 hasConcept C141071460 @default.
• W2276391444 hasConcept C142724271 @default.
• W2276391444 hasConcept C143998085 @default.
• W2276391444 hasConcept C197934379 @default.
• W2276391444 hasConcept C204787440 @default.
• W2276391444 hasConcept C27081682 @default.
• W2276391444 hasConcept C2776694085 @default.
• W2276391444 hasConcept C2777389519 @default.
• W2276391444 hasConcept C2777802072 @default.
• W2276391444 hasConcept C509974204 @default.
• W2276391444 hasConcept C71924100 @default.
• W2276391444 hasConceptScore W2276391444C126322002 @default.
• W2276391444 hasConceptScore W2276391444C141071460 @default.
• W2276391444 hasConceptScore W2276391444C142724271 @default.
• W2276391444 hasConceptScore W2276391444C143998085 @default.
• W2276391444 hasConceptScore W2276391444C197934379 @default.
• W2276391444 hasConceptScore W2276391444C204787440 @default.
• W2276391444 hasConceptScore W2276391444C27081682 @default.
• W2276391444 hasConceptScore W2276391444C2776694085 @default.
• W2276391444 hasConceptScore W2276391444C2777389519 @default.
• W2276391444 hasConceptScore W2276391444C2777802072 @default.
• W2276391444 hasConceptScore W2276391444C509974204 @default.
• W2276391444 hasConceptScore W2276391444C71924100 @default.
• W2276391444 hasFunder F4320307779 @default.
• W2276391444 hasIssue "7" @default.
• W2276391444 hasLocation W22763914441 @default.
• W2276391444 hasLocation W22763914442 @default.
• W2276391444 hasLocation W22763914443 @default.
• W2276391444 hasLocation W22763914444 @default.
• W2276391444 hasOpenAccess W2276391444 @default.
• W2276391444 hasPrimaryLocation W22763914441 @default.
• W2276391444 hasRelatedWork W2004862885 @default.
• W2276391444 hasRelatedWork W2013021062 @default.
• W2276391444 hasRelatedWork W2079914139 @default.
• W2276391444 hasRelatedWork W2088650889 @default.
• W2276391444 hasRelatedWork W2405819935 @default.
• W2276391444 hasRelatedWork W2462822954 @default.
• W2276391444 hasRelatedWork W2527516493 @default.
• W2276391444 hasRelatedWork W2566967253 @default.

• next